Association of MammaPrint index and 3-year outcome of patients with HR+HER2-early-stage breast cancer treated with chemotherapy with or without anthracycline

被引：0

作者：

O'Shaughnessy, Joyce

Graham, Cathy Lynne

Whitworth, Pat

Beitsch, Peter D.

Osborne, Cynthia R. C.

Rahman, Rakhshanda Layeequr

Brown, Eric Allen

Gold, Linsey P.

Johnson, Nathalie Mcdowell

Brufsky, Adam

Ramaswamy, Harshini

Stivers, Nicole

Menicucci, Andrea

Audeh, M. William

机构：

[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA

[2] Emory Univ, Atlanta, GA USA

[3] Nashville Breast Ctr, Nashville, TN USA

[4] Dallas Surg Grp, Dallas, TX USA

[5] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA

[6] Comprehens Breast Care, Troy, MI USA

[7] Legacy Hlth Syst, Portland, OR USA

[8] Univ Pittsburgh, Pittsburgh, PA USA

[9] Agendia Inc, Med Affairs, Irvine, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

511

引用

页数：1

共 50 条

[31] Investigating the immune profile of early stage HER2+breast cancer patients receiving chemotherapy and HER2-targeted therapies
Collins, Denis M.
Gaynor, Nicola
Madden, Stephen
Toomey, Sinead
Qiu, Ji
Blayney, Jaine
Blanco, Alfonso
Fletcher, Jean
Moran, Barry
Kaukonen, Damien
Ramirez, Javier Sanchez
Kay, Elaine
O'Connor, Darran
Teiserskiene, Ausra
Eustace, Alex
Kennedy, Richard
LaBaer, Joshua
Gallagher, William
Hennessy, Bryan
Crown, John
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 487 - 487
[32] Late relapse rates in patients with early-stage hormone receptor-positive and HER2+breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy
Altundag, Kadri
JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (06) : 1042 - 1042
[33] Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
Tiwari, Shruti Rakesh
Raska, Paola
Moore, Halle C. F.
Emamekhoo, Hamid
Abraham, Jame
Budd, G. Thomas
Montero, Alberto J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] Outcomes of patients with ER+/HER2+non-metastatic breast cancer treated with trastuzumab without chemotherapy
Nguy, Susanna
Wu, S. Peter
Oh, Cheongeun
Gerber, Naamit K.
CANCER RESEARCH, 2020, 80 (04)
[35] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
Ratti, Riccardo
Coccorullo, Zaira
Guarneri, Domenico
Colloca, Giuseppe
Venturino, Antonella
Addamo, Gianfranco
Campora, Elisabetta
ANNALS OF ONCOLOGY, 2009, 20
[36] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
Ratti, R.
Coccorullo, Z.
Guarneri, D.
Colloca, G.
Addamo, G.
Venturino, A.
Campora, E.
ANNALS OF ONCOLOGY, 2009, 20 : 45 - 45
[37] Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan
Shimomura, Akihiko
Sagara, Yasuaki
Koto, Ryo
Fujiwara, Masakazu
Kanemura, Yuka
Kitagawa, Hiroshi
Saji, Shigehira
BREAST CANCER, 2024, 31 (04) : 581 - 592
[38] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
Nguy, Susanna
Wu, S. Peter
Oh, Cheongeun
Gerber, Naamit K.
BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 815 - 830
[39] Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
Susanna Nguy
S. Peter Wu
Cheongeun Oh
Naamit K. Gerber
Breast Cancer Research and Treatment, 2021, 187 : 815 - 830
[40] The impact of neoadjuvant chemotherapy on overall survival in patients with early-stage HER2-positive breast cancer
Champion, Nicholas
Azab, Basem
Abeysekera, Aravinda
Kim, Sara
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 201 - 201

← 1 2 3 4 5 →